ToxSci Advance Access originally published online on May 5, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Toxicological Sciences 80, 225-229 (2004)
Toxicological Sciences vol. 80 no. 2 © Society of Toxicology 2004; all rights reserved.
Human Carcinogenic Risk Evaluation: An Alternative Approach to the Two-Year Rodent Bioassay
Department of Pathology and Microbiology, University of Nebraska Medical Center, 983135 Nebraska Medical Center, Omaha, Nebraska 68198-3135
Received March 29, 2004; accepted April 21, 2004
An approach to the evaluation of carcinogenic risk resulting from exposure to a given chemical is presented in place of a reliance on two-year rodent bioassays. An emphasis is placed on evaluation of the potential DNA reactivity or increased cell proliferation that can be produced by a chemical. The special cases of immunosuppressive and estrogenic chemicals are considered. These evaluations are proposed to involve a combination of in vitro assays, computerized models, and short-term (up to 13 weeks) bioassays in rodents. The emphasis is on mechanistic understanding and evaluation of the dose response and relevance to humans.
Key Words: mechanism; DNA reactive; non-genotoxic; estrogen; immunosuppressive; cell proliferation.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
A. R. Boobis, S. M. Cohen, N. G. Doerrer, S. M. Galloway, P. J. Haley, G. C. Hard, F. G. Hess, J. S. Macdonald, S. Thibault, D. C. Wolf, et al. A Data-Based Assessment of Alternative Strategies for Identification of Potential Human Cancer Hazards Toxicol Pathol, October 1, 2009; 37(6): 714 - 732. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. MacDonald and R. T. Robertson Toxicity Testing in the 21st Century: A View from the Pharmaceutical Industry Toxicol. Sci., July 1, 2009; 110(1): 40 - 46. [Full Text] [PDF] |
||||
![]() |
J. L. Bussiere, P. Martin, M. Horner, J. Couch, M. Flaherty, L. Andrews, J. Beyer, and C. Horvath Alternative Strategies for Toxicity Testing of Species-Specific Biopharmaceuticals International Journal of Toxicology, May 1, 2009; 28(3): 230 - 253. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Deguchi, T. Yamada, Y. Hirose, H. Nagahori, M. Kushida, K. Sumida, T. Sukata, Y. Tomigahara, K. Nishioka, S. Uwagawa, et al. Mode of Action Analysis for the Synthetic Pyrethroid Metofluthrin-Induced Rat Liver Tumors: Evidence for Hepatic CYP2B Induction and Hepatocyte Proliferation Toxicol. Sci., March 1, 2009; 108(1): 69 - 80. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Fielden, R. Brennan, and J. Gollub A Gene Expression Biomarker Provides Early Prediction and Mechanistic Assessment of Hepatic Tumor Induction by Nongenotoxic Chemicals Toxicol. Sci., September 1, 2007; 99(1): 90 - 100. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Jacobs Prediction of 2-Year Carcinogenicity Study Results for Pharmaceutical Products: How Are We Doing? Toxicol. Sci., November 1, 2005; 88(1): 18 - 23. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Bucher and C. Portier Human Carcinogenic Risk Evaluation, Part V: The National Toxicology Program Vision for Assessing the Human Carcinogenic Hazard of Chemicals Toxicol. Sci., December 1, 2004; 82(2): 363 - 366. [Abstract] [Full Text] [PDF] |
||||


